• chevron_left Previous | Next chevron_right

    COVID-19 vaccines coding guide

    The CPT Editorial Panel has approved unique codes for multiple COVID-19 vaccines, as well as administration codes for each dose of those vaccines. This list will be updated as more codes are approved.

    Manufacturer Vaccine code Description Administration codes

    Pfizer

    91300

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use

    • 0001A (1st dose)

    • 0002A (2nd dose)

    • 0003A (3rd dose)

    • 0004A (booster)

    Moderna

    91301

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use

    • 0011A (1st dose)

    • 0012A (2nd dose)

    • 0013A (3rd dose)

    Moderna half-dose booster

    91306

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25mL dosage, for intramuscular use

    • 0064A (booster)

    AstraZeneca/Oxford

    91302

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use

    • 0021A (1st dose)

    • 0022A (2nd dose)
    Janssen (Johnson & Johnson) 91303 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use

    • 0031A (single-dose vaccine)

    • 0034A (booster)
    Novavax 91304 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use

    • 0041A (1st dose)

    • 0042A (2nd dose)
    Pfizer (tris-sucrose formulation) 91305 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use

    • 0051A (first dose)

    • 0052A (second dose)

    • 0053A (third dose)

     

    All codes are provisional, pending Emergency Use Authorization or approval by the U.S. Food and Drug Administration. The AMA has published a special edition CPT Assistant guide, which includes an appendix to help identify each vaccine’s product code and administration code.

    The AAFP is monitoring every aspect of the COVID-19 vaccine development process, including the Food and Drug Administration's Emergency Use Authorization reviews. Visit aafp.org/covidvaccine for updates to help prepare your practice and patients for the vaccines.

    Posted on Jan 06, 2021 by FPM Editors

    chevron_left Previous | Next chevron_right

    Topics

    Other Blogs

    Feed

    Disclaimer: The opinions and views expressed here are those of the authors and do not necessarily represent or reflect the opinions and views of the American Academy of Family Physicians. This blog is not intended to provide medical, financial, or legal advice. Some payers may not agree with the advice given. This is not a substitute for current CPT and ICD-9 manuals and payer policies. All comments are moderated and will be removed if they violate our Terms of Use.

    Copyright © 2020 American Academy of Family Physicians.  All rights Reserved.